Research Roundup

COPD treatments; celecoxib; HRT and risk of venous thromboembolism… Debbie Rigby takes a look at the latest in research news

Dual combination therapy versus long‐acting bronchodilators alone for COPD

A systematic review and network meta‐analysis of 99 studies (n=101,311) has concluded that LABA/LAMA combination bronchodilators reduce COPD exacerbations more than LABA/ICS combination, LAMA, and LABA in the high‐ and low-risk populations. Combination therapies appear more effective than monotherapies for improving symptom and quality‐of‐life scores. ICS‐containing inhalers are associated with an increased risk of pneumonia.

Cochrane Database of Systematic Reviews 2018, Issue 12.


Safety of celecoxib versus traditional nonsteroidal anti-inflammatory drugs in older patients with arthritis

In this large Korean retrospective cohort study of older people with arthritis, celecoxib was associated with decreased risk of GI bleeding compared with traditional NSAIDs when treatment lasted for ≥120 days, but such a relationship was not found among subgroup patients with no concomitant use of gastroprotective prophylaxis. Celecoxib users were more likely to experience CV and renal events than traditional NSAIDs users, and a dose-dependent risk relationship was observed with celecoxib.

Journal of Pain Research 2018;11:3211-9.


Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD)

A Cochrane review has concluded that fixed-dose combination (FDC) of aclidinium/formoterol improves dyspnoea and lung function compared to aclidinium, formoterol or placebo. Quality of life was better with combination compared to formoterol or placebo. There was no evidence of a difference between FDC and monotherapy or placebo for exacerbations, hospital admissions, mortality, non-fatal SAEs or adverse events.

Cochrane Database of Systematic Reviews 2018, Issue 12.


Use of hormone replacement therapy and risk of venous thromboembolism

Analysis of UK general practices shows oral therapy is associated with a significantly increased risk of venous thromboembolism compared to no exposure, and to both oestrogen only preparations and combination therapy. Compared with no exposure, conjugated equine oestrogen with medroxyprogesterone acetate had the highest risk and estradiol with dydrogesterone had the lowest risk. Transdermal preparations were not associated with risk of venous thromboembolism.

BMJ 2019;364:k4810.

Previous Beyond the agreement
Next How many Australians are accessing unapproved medicinal cannabis?

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

No Comment

Leave a reply